768 results on '"Salido, Eduardo"'
Search Results
2. Inhibition of hepatic oxalate overproduction ameliorates metabolic dysfunction-associated steatohepatitis
3. Efficient and safe therapeutic use of paired Cas9-nickases for primary hyperoxaluria type 1
4. Restored glyoxylate metabolism after AGXT gene correction and direct reprogramming of primary hyperoxaluria type 1 fibroblasts
5. Postcolonoscopy colorectal cancer: Prevalence, categorization and root-cause analysis based on the World Endoscopic Organization system
6. ARID2 deficiency promotes tumor progression and is associated with higher sensitivity to chemotherapy in lung cancer
7. Determinants of Kidney Failure in Primary Hyperoxaluria Type 1: Findings of the European Hyperoxaluria Consortium
8. Oral Treatment With an Engineered Uricase, ALLN-346, Reduces Hyperuricemia, and Uricosuria in Urate Oxidase-Deficient Mice
9. Lactate dehydrogenase A inhibitors with a 2,8-dioxabicyclo[3.3.1]nonane scaffold: A contribution to molecular therapies for primary hyperoxalurias
10. Different phenotypic outcome due to site-specific phosphorylation in the cancer-associated NQO1 enzyme studied by phosphomimetic mutations
11. New salicylic acid derivatives, double inhibitors of glycolate oxidase and lactate dehydrogenase, as effective agents decreasing oxalate production
12. Improved Outcome of Infantile Oxalosis Over Time in Europe: Data From the OxalEurope Registry
13. In vivo CRISPR-Cas9 inhibition of hepatic LDH as treatment of primary hyperoxaluria
14. Modulation of the K/BxN arthritis mouse model and the effector functions of human fibroblast‐like synoviocytes by liver X receptors.
15. Treatment of early borderline lesions in low immunological risk kidney transplant patients: a Spanish multicenter, randomized, controlled parallel-group study protocol: the TRAINING study
16. FRI-152-YI Gene editing to treat liver metabolic disorders: harnessing paired Cas9-Nickases for efficient and safe treatment of primary hyperoxaluria type 1
17. LBP-017 Liver-kidney crosstalk: the influence of hepatic oxalate release on kidney gluconeogenesis
18. Structural basis of the pleiotropic and specific phenotypic consequences of missense mutations in the multifunctional NAD(P)H:quinone oxidoreductase 1 and their pharmacological rescue
19. Epigenomic and transcriptional profiling identifies impaired glyoxylate detoxification in NAFLD as a risk factor for hyperoxaluria
20. High Expression of FOXP2 Is Associated with Worse Prognosis in Glioblastoma
21. Clinical, biological, and prognostic implications of SF3B1 co-occurrence mutations in very low/low- and intermediate-risk MDS patients
22. Insights into the pathogenesis of primary hyperoxaluria type I from the structural dynamics of alanine:glyoxylate aminotransferase variants
23. Renal Disease in Obesity, Metabolic Syndrome and Diabesity
24. Patients with primary hyperoxaluria type 2 have significant morbidity and require careful follow-up
25. Insights into the pathogenesis of primary hyperoxaluria type I from the structural dynamics of alanine:glyoxylate aminotransferase variants
26. Flow Cytometry as a New Accessible Method to Evaluate Diagnostic Osmotic Changes in Patients with Red Blood Cell Membrane Defects.
27. Natural (and Unnatural) Small Molecules as Pharmacological Chaperones and Inhibitors in Cancer
28. Randomized Controlled Trial Assessing the Impact of Tacrolimus Versus Cyclosporine on the Incidence of Posttransplant Diabetes Mellitus
29. Specific Inhibition of Hepatic Lactate Dehydrogenase Reduces Oxalate Production in Mouse Models of Primary Hyperoxaluria
30. siRNA Therapeutics to Treat Liver Disorders
31. P1480: CLINICAL AND GENETIC STUDY OF HEREDITARY SPHEROCYTOSIS IN THE SPANISH POPULATION.
32. A new HDV mouse model identifies mitochondrial antiviral signaling protein (MAVS) as a key player in IFN-β induction
33. Vascular Damage and Kidney Transplant Outcomes: An Unfriendly and Harmful Link
34. Contributors
35. Vitamin B6-dependent enzymes and disease
36. Consensus document for the diagnosis and treatment of pyruvate kinase deficiency
37. Documento de consenso para el diagnóstico y tratamiento del déficit de piruvato quinasa
38. Caenorhabditis elegans AGXT-1 is a mitochondrial and temperature-adapted ortholog of peroxisomal human AGT1: New insights into between-species divergence in glyoxylate metabolism
39. Plasma matrix metalloproteinase 9 as an early surrogate biomarker of advanced colorectal neoplasia
40. Inhibition of Glycolate Oxidase With Dicer-substrate siRNA Reduces Calcium Oxalate Deposition in a Mouse Model of Primary Hyperoxaluria Type 1
41. Glycolate Oxidase Is a Safe and Efficient Target for Substrate Reduction Therapy in a Mouse Model of Primary Hyperoxaluria Type I
42. Structural and functional insights on the roles of molecular chaperones in the mistargeting and aggregation phenotypes associated with primary hyperoxaluria type I
43. Renal Disease in Obesity, Metabolic Syndrome and Diabesity
44. Supplementary Table 1 from Hematopoietic Prostaglandin D Synthase Suppresses Intestinal Adenomas in ApcMin/+ Mice
45. Data from Hematopoietic Prostaglandin D Synthase Suppresses Intestinal Adenomas in ApcMin/+ Mice
46. Glucose homeostasis changes and pancreatic β-cell proliferation after switching to cyclosporin in tacrolimus-induced diabetes mellitus
47. Cambios en la homeostasis de la glucosa y la proliferación de la célula beta pancreática tras el cambio a ciclosporina en la diabetes inducida por tacrolimus
48. Molecular therapy of primary hyperoxaluria
49. Phosphorylation of Thr9 Affects the Folding Landscape of the N-Terminal Segment of Human AGT Enhancing Protein Aggregation of Disease-Causing Mutants
50. The lower limits for protein stability and foldability in primary hyperoxaluria type I
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.